Skip to main content
SpringerLink
Log in

Pharmacogenetic association of KCNJ11 (E23K) variant with therapeutic response to sulphonylurea (glibenclamide) in Iranian patients

  • Letter to Editor
  • Published:
International Journal of Diabetes in Developing Countries Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840–6.

    Article  CAS  PubMed  Google Scholar 

  2. Vella A. Pharmacogenetics for type 2 diabetes: practical considerations for study design. J Diabetes Sci Technol. 2009;3:705–9.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Rastegari A, Rabbani M, Mirmohammad Sadeghi H, Faghih Imani E, Hasanzadeh A, Moazen F. Association of KCNJ11 (E23K) gene polymorphism with susceptibility to type 2 diabetes in Iranian patients. Adv Biomed Res. 2015;4(1).

  4. Inoue H, Ferrer J, Warren-Perry M, Zhang Y, Millns H, Turner RC, et al. Sequence variants in the pancreatic islet β-cell inwardly rectifying K+ channel Kir6. 2 (Bir) gene: identification and lack of role in Caucasian patients with NIDDM. Diabetes. 1997;46(3):502–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

    Ali Rastegari, Mohammad Rabbani, Hamid Mirmohammad Sadeghi & Fatemeh Moazen

  2. Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Science, Isfahan, Iran

    Elham Faghih Imani

  3. Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Science, Isfahan, Iran

    Akbar Hasanzadeh

Authors
  1. Ali Rastegari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammad Rabbani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hamid Mirmohammad Sadeghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elham Faghih Imani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akbar Hasanzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fatemeh Moazen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Rabbani.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rastegari, A., Rabbani, M., Sadeghi, H.M. et al. Pharmacogenetic association of KCNJ11 (E23K) variant with therapeutic response to sulphonylurea (glibenclamide) in Iranian patients. Int J Diabetes Dev Ctries 35, 630–631 (2015). https://doi.org/10.1007/s13410-015-0316-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13410-015-0316-1

Keywords

Search

Navigation